• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bank Of America, Morgan Stanley And Other 3 Stocks To Watch Heading Into Tuesday

    7/16/24 3:08:43 AM ET
    $BAC
    $FBK
    $KYTX
    $MS
    Major Banks
    Finance
    Major Banks
    Finance
    Get the next $BAC alert in real time by email

    With U.S. stock futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:

    • Wall Street expects Bank of America Corporation (NYSE:BAC) to report quarterly earnings at 80 cents per share on revenue of $25.22 billion before the opening bell. Bank of America shares gained 0.1% to $41.94 in after-hours trading.
    • FB Financial Corporation (NYSE:FBK) posted better-than-expected results for its second quarter on Monday. FB Financial shares rose 0.5% to $43.03 in the after-hours trading session.
    • Analysts are expecting Morgan Stanley (NYSE:MS) to post quarterly earnings at $1.65 per share on revenue of $14.3 billion. The company will release earnings before the markets open. Morgan Stanley shares rose 0.8% to $106.14 in after-hours trading.

    Check out our premarket coverage here

    • Kyverna Therapeutics, Inc. (NASDAQ:KYTX) shares rose sharply in after-hours trading on Monday after the company announced it received FDA Regenerative Medicine Advanced Therapy designation for KYV-101 in the treatment of patients with refractory stiff-person syndrome. Kyverna Therapeutics shares surged 7.5% to $10.65 in the after-hours trading session.
    • Analysts expect UnitedHealth Group Incorporated (NYSE:UNH) to post quarterly earnings at $6.66 per share on revenue of $98.84 billion after the closing bell. UnitedHealth shares rose 0.9% to $519.99 in after-hours trading.

    Check This Out:

    • Over $18M Bet On This Tech Stock? Check Out These 4 Stocks Insiders Are Buying
    Get the next $BAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BAC
    $FBK
    $KYTX
    $MS

    CompanyDatePrice TargetRatingAnalyst
    UnitedHealth Group Incorporated
    $UNH
    4/22/2026$400.00Hold → Buy
    Argus
    UnitedHealth Group Incorporated
    $UNH
    4/7/2026$300.00Reduce → Hold
    HSBC Securities
    Morgan Stanley
    $MS
    4/7/2026$196.00Neutral → Buy
    UBS
    FB Financial Corporation
    $FBK
    4/7/2026$62.00Mkt Perform → Strong Buy
    Raymond James
    FB Financial Corporation
    $FBK
    4/3/2026$65.00Neutral → Overweight
    Piper Sandler
    FB Financial Corporation
    $FBK
    4/2/2026$65.00Neutral → Overweight
    Piper Sandler
    UnitedHealth Group Incorporated
    $UNH
    4/1/2026$330.00Mkt Perform → Outperform
    Raymond James
    Bank of America Corporation
    $BAC
    4/1/2026$57.00Hold → Buy
    HSBC Securities
    More analyst ratings

    $BAC
    $FBK
    $KYTX
    $MS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Grossman Eric F

    4 - MORGAN STANLEY (0000895421) (Issuer)

    4/20/26 4:23:01 PM ET
    $MS
    Investment Bankers/Brokers/Service
    Finance

    SEC Form 4 filed by Simkowitz Daniel A

    4 - MORGAN STANLEY (0000895421) (Issuer)

    4/17/26 4:41:18 PM ET
    $MS
    Investment Bankers/Brokers/Service
    Finance

    SEC Form 4 filed by Saperstein Andrew M

    4 - MORGAN STANLEY (0000895421) (Issuer)

    4/17/26 4:38:02 PM ET
    $MS
    Investment Bankers/Brokers/Service
    Finance

    $BAC
    $FBK
    $KYTX
    $MS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UnitedHealth upgraded by Argus with a new price target

    Argus upgraded UnitedHealth from Hold to Buy and set a new price target of $400.00

    4/22/26 7:35:11 AM ET
    $UNH
    Medical Specialities
    Health Care

    UnitedHealth upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded UnitedHealth from Reduce to Hold and set a new price target of $300.00

    4/7/26 8:51:26 AM ET
    $UNH
    Medical Specialities
    Health Care

    Morgan Stanley upgraded by UBS with a new price target

    UBS upgraded Morgan Stanley from Neutral to Buy and set a new price target of $196.00

    4/7/26 8:36:03 AM ET
    $MS
    Investment Bankers/Brokers/Service
    Finance

    $BAC
    $FBK
    $KYTX
    $MS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Bank Of America Corp /De/ bought $4,303 worth of shares (343 units at $12.55) and sold $4,202 worth of shares (343 units at $12.25) (SEC Form 4)

    4 - BANK OF AMERICA CORP /DE/ (0000070858) (Reporting)

    1/28/26 1:23:38 PM ET
    $BAC
    Major Banks
    Finance

    Large owner Bank Of America Corp /De/ bought $10,319 worth of shares (1,000 units at $10.32) and sold $10,540 worth of shares (1,000 units at $10.54) (SEC Form 4)

    4 - BANK OF AMERICA CORP /DE/ (0000070858) (Reporting)

    12/22/25 5:14:47 PM ET
    $BAC
    Major Banks
    Finance

    Director Seidenberg Beth C bought $999,998 worth of shares (133,333 units at $7.50) (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    12/22/25 11:43:43 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BAC
    $FBK
    $KYTX
    $MS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

    Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS Data underscore potential for miv-cel to become the first and only approved treatment for SPS, fundamentally changing the treatment paradigm for patients and caregivers Company to host conference call on Wednesday, April 22, 2026, at 7:00 am ET EMERYVILLE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced positive prima

    4/21/26 6:45:00 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UnitedHealth Group Reports First Quarter 2026 Results

    First Quarter 2026 Revenues of $111.7 Billion Grew 2% Year-over-Year Earnings of $6.90 Per Share and Adjusted Earnings of $7.23 Per Share Full Year 2026 Earnings Outlook Raised to Greater Than $17.35 Per Share; Adjusted Earnings of Greater Than $18.25 Per Share To view this information in a different format, including graphics, published on our website, click here: https://www.unitedhealthgroup.com/content/dam/UHG/PDF/investors/2026/unh-reports-first-quarter-2026-results.pdf UnitedHealth Group (NYSE:UNH) today reported first quarter 2026 results, with performance supported by actions taken over the last several quarters. This press release features multimedia. View the full rel

    4/21/26 5:55:00 AM ET
    $UNH
    Medical Specialities
    Health Care

    Alaska Air Group and Bank of America Expand Long-Standing Credit Card Partnership

    Strengthens co-branded credit card portfolio and supports growth of the Atmos Rewards programCardholders will benefit from enhanced value across the full suite of Atmos Rewards credit cards over timeAlaska Air Group will move toward a single issuer for its Atmos Rewards credit cards The extended partnership is expected to drive incremental value for both companiesSEATTLE and CHARLOTTE, N.C., April 20, 2026 /PRNewswire/ -- Alaska Air Group Inc. (NYSE: ALK) and Bank of America (NYSE:BAC) today announced a multi-year extension of their co-branded credit card agreement – a continuation of the bank's largest co-brand partnership. For more than 30 years, the strategic partnership has put an indust

    4/20/26 5:50:00 PM ET
    $ALK
    $BAC
    Air Freight/Delivery Services
    Consumer Discretionary
    Major Banks
    Finance

    $BAC
    $FBK
    $KYTX
    $MS
    SEC Filings

    View All

    Kyverna Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)

    4/22/26 7:00:13 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)

    4/21/26 6:45:14 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form FWP filed by Bank of America Corporation

    FWP - BANK OF AMERICA CORP /DE/ (0000070858) (Subject)

    4/21/26 5:49:10 PM ET
    $BAC
    Major Banks
    Finance

    $BAC
    $FBK
    $KYTX
    $MS
    Financials

    Live finance-specific insights

    View All

    Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

    Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS Data underscore potential for miv-cel to become the first and only approved treatment for SPS, fundamentally changing the treatment paradigm for patients and caregivers Company to host conference call on Wednesday, April 22, 2026, at 7:00 am ET EMERYVILLE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced positive prima

    4/21/26 6:45:00 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UnitedHealth Group Reports First Quarter 2026 Results

    First Quarter 2026 Revenues of $111.7 Billion Grew 2% Year-over-Year Earnings of $6.90 Per Share and Adjusted Earnings of $7.23 Per Share Full Year 2026 Earnings Outlook Raised to Greater Than $17.35 Per Share; Adjusted Earnings of Greater Than $18.25 Per Share To view this information in a different format, including graphics, published on our website, click here: https://www.unitedhealthgroup.com/content/dam/UHG/PDF/investors/2026/unh-reports-first-quarter-2026-results.pdf UnitedHealth Group (NYSE:UNH) today reported first quarter 2026 results, with performance supported by actions taken over the last several quarters. This press release features multimedia. View the full rel

    4/21/26 5:55:00 AM ET
    $UNH
    Medical Specialities
    Health Care

    Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

    100% of patients achieved rapid, sustained improvements across MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial  Totality of efficacy and safety data reinforces miv-cel's differentiated and potential best-in-class profile for delivering durable, drug-free, disease-free remission with a single dose Company to host conference call on Wednesday, April 22, 2026, at 7:00 am ET EMERYVILLE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced positive longer-term follow-up data from the Phase 2 por

    4/20/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BAC
    $FBK
    $KYTX
    $MS
    Leadership Updates

    Live Leadership Updates

    View All

    Alaska Air Group and Bank of America Expand Long-Standing Credit Card Partnership

    Strengthens co-branded credit card portfolio and supports growth of the Atmos Rewards programCardholders will benefit from enhanced value across the full suite of Atmos Rewards credit cards over timeAlaska Air Group will move toward a single issuer for its Atmos Rewards credit cards The extended partnership is expected to drive incremental value for both companiesSEATTLE and CHARLOTTE, N.C., April 20, 2026 /PRNewswire/ -- Alaska Air Group Inc. (NYSE: ALK) and Bank of America (NYSE:BAC) today announced a multi-year extension of their co-branded credit card agreement – a continuation of the bank's largest co-brand partnership. For more than 30 years, the strategic partnership has put an indust

    4/20/26 5:50:00 PM ET
    $ALK
    $BAC
    Air Freight/Delivery Services
    Consumer Discretionary
    Major Banks
    Finance

    Morgan Stanley Investment Management Enters Digital Investments Universe With Launch of Morgan Stanley Bitcoin Trust

    Morgan Stanley Investment Management (MSIM) announced today the launch of Morgan Stanley Bitcoin Trust (NYSE:MSBT), an exchange-traded product (ETP) that seeks to track the performance of bitcoin. MSIM is the first U.S. bank-affiliated asset manager to offer a cryptocurrency ETP, and reflects a continued, firmwide focus by Morgan Stanley to develop digital asset solutions designed to meet evolving client demand. "We are proud to introduce MSBT to the marketplace and believe this new ETP aligns with long-term trends in financial innovation and serves to strengthen the range of investments we provide investors," said Ben Huneke, Head of Morgan Stanley Investment Management. "MSBT is an ex

    4/8/26 8:25:00 AM ET
    $MS
    Investment Bankers/Brokers/Service
    Finance

    Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors

    Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization Andrew Miller adds deep clinical development and product approval experience to support Kyverna's next phase of growth EMERYVILLE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointments of Sravan K. Emany and Andrew Miller, Ph.D. to its Board of Directors. Mr. Emany will assume the role of Audit Committee Chair, following the transition of Dan Spiegelman from this position, who has stepped d

    2/24/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BAC
    $FBK
    $KYTX
    $MS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Bank of America Corporation

    SC 13D/A - BANK OF AMERICA CORP /DE/ (0000070858) (Filed by)

    12/13/24 4:29:10 PM ET
    $BAC
    Major Banks
    Finance

    Amendment: SEC Form SC 13G/A filed by FB Financial Corporation

    SC 13G/A - FB Financial Corp (0001649749) (Subject)

    11/14/24 1:28:34 PM ET
    $FBK
    Major Banks
    Finance

    SEC Form SC 13G filed by Kyverna Therapeutics Inc.

    SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)

    11/12/24 7:23:31 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care